$OBMP is a small biotech player we have covered a few times recently, noting that the stock looked increasingly interesting given its R&D assets as either a very cheap buyout target or a deep value lotto ticket in the space for speculative funds. The week is turning out to be a vindication of that outlook as the stock is starting to power higher on the company’s announcement on Wednesday that the key regulatory authority in this matter has granted full authorization to move ahead with the protocol proposed for the Phase 2/3 clinical trial of ProscaVax.

This is the big news the company was waiting for, and should put them on the prostate cancer pipeline game board, along with key players such as Seattle Genetics, Inc. (NASDAQ:SGEN), Inovio Pharmaceuticals (NASDAQ:INO), Nymox Pharmaceutical Corporation (NASDAQ:NYMX). The key news came from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI in Mexico. In the study, ProscaVax, OncBioMune’s lead experimental therapeutic cancer vaccine, will be evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients.
https://www.journaltranscript.com/2017/01/onc...s-surging/